Trump Selects Heidi Overton, Senior Domestic Policy Adviser, as F.D.A. Chief Nominee
President Trump has chosen Dr. Heidi Overton, a key figure in his domestic policy team, to lead the Food and Drug Administration, according to people familiar with the decision. Th…
President Trump has chosen Dr. Heidi Overton, a
President Trump has chosen Dr. Heidi Overton, a key figure in his domestic policy team, to lead the Food and Drug Administration, according to people familiar with the decision. The pick signals a strong push to align the agency with the administration’s health priorities, particularly those championed by Health Secretary Robert F. Kennedy Jr.
Overton, a physician and policy adviser, has been a vocal advocate against abortion rights, a stance that has defined much of her public profile. Her nomination is expected to face scrutiny from Senate Democrats, who have already signaled concerns about her ideological alignment and lack of direct regulatory experience.
Supporters within the administration view her as a reliable ally for Kennedy’s “Make America Healthy Again” agenda, which emphasizes reducing chronic disease, overhauling nutritional guidelines, and challenging established pharmaceutical practices. Overton has privately pushed for stricter oversight of vaccine ingredients and food additives, though she has not publicly detailed specific policy shifts.
Critics, however, worry that her appointment could under…
Critics, however, worry that her appointment could undermine the FDA’s scientific independence. Public health experts note that the agency’s credibility rests on evidence-based decisions, and they question whether Overton’s ideological commitments will override that mandate. The agency is currently navigating a wave of resignations and internal turmoil over recent policy reversals.
If confirmed, Overton would inherit a sprawling organization managing everything from drug approvals to food safety. Her immediate priorities are likely to include expediting reviews of certain therapies and revisiting regulatory frameworks for dietary supplements, areas where Kennedy has pressed for change.
Senate confirmation hearings are not yet scheduled, but aides expect a contentious battle. Overton’s backers argue her fresh perspective is exactly what the FDA needs, while opponents frame her nomination as a political reward that prioritizes ideology over public health. The White House has not commented on the timeline for a formal announcement.